Lynparza phase III PROfound trial in HRR mutation-selected metastatic castration-resistant prostate cancer met primary endpoint

Image: Lynparza is currently approved in 64 countries, including those in the EU, for the maintenance treatment of platinum-sensitive relapsed ovarian cancer regardless of BRCA status. Photo: courtesy of AstraZeneca.